MetaboliccareToday.com

Today the FDA approves the first oral small molecule GLP-1 for obesity. Orforglipron, brand name Foundayo, can be taken irrespective of food or other medications. investor.lilly.com/news-releases/…

Part 1 of our 2‑part video series is live. Co‑authors @nje_kim and Anna Naumova (both of @UWMedicine) discuss the scientific background and key findings from their @ObesitySociety study, including MRI‑based assessment of liver fat. ▶️ Watch: docwirenews.com/post/what-mri-…

Today the FDA approved the first once-weekly insulin. Insulin icodec, now brand name Awiqli, demonstrated superior a1c reduction to daily insulin glargine with a1c reduction of 1.55% compared to 1.35%, in addition to 6 less injections per week in the ONWARDS phase 3 trial. Now clinicians must become comfortable with switching daily insulin users to an equivalent weekly dose and start and titrate new users. novonordisk-us.com/media/news-arc…

The 2026 @TheAACE Diabetes Algorithm brings a new complications‑focused model for T2D care. @scottisaacsmd new article covers updates in prediabetes, ASCVD, CKD, HF & MASLD/MASH. Read his full breakdown: docwirenews.com/post/type-2-di… @MWeintraubMD @Neil_Iyengar @BevTchangMD

Women with common metabolic risk factors may face a much higher risk of liver fibrosis than men. In this interview, Jennifer Dodge (@KeckMedicineUSC) explains the research, possible hormonal drivers, and what it means for screening & prevention. 🎥 docwirenews.com/post/why-women…

The FDA has approved the first and only therapy for acquired hypothalamic obesity. Setmelanotide (IMCIVREE) now carries an expanded indication for patients 4+, backed by phase 3 data showing an 18.4% placebo‑adjusted BMI reduction. docwirenews.com/post/fda-appro… @MWeintraubMD

Next-gen multi-receptor incretin agonists (GLP-1/GIP, GLP-1/glucagon, GLP-1/amylin, triple agonists) and oral small‑molecule GLP-1 RAs like orforglipron can produce >20% weight loss, better glycemic control, and kidney/liver benefits but we’re still figuring out how to manage tolerability, sarcopenia risk, and long-term use in a chronic disease. academic.oup.com/edrv/article-a…

Positive Phase 2 data for aleniglipron, an investigational once‑daily oral GLP‑1 RA: ✔️ Up to 16.3% weight loss at 44 weeks ✔️ Strong tolerability + no weight‑loss plateau ✔️ Low AE‑related discontinuations A potential new oral option in obesity treatment. docwirenews.com/post/aleniglip…

Great takeaways on the fundamentals of body composition analysis (BCAs) from @elucasmd yesterday at the @WeillCornell #Obesity #Medicine didactics: 👉 Unless you're doing a cadaveric dissection, all BCA modalities are giving calculated estimates of body compositions 👉 Thankfully, accessible devices like body impedance analyzers (BIA) are approaching gold-standard accuracy of MRIs: eg) muscle mass has a 97% correlation with MRI [HT @PsychoDietitian] 👉 All BCA modalities have their pros and cons, with some (eg, BIA) being very dependent on hydration status 👉 Discuss results in comparison to the patient's prior data, not to the population at large, since their position on the standard curve of the population may be modifiable only to a degree

Setmelanotide, an MC4R agonist, is now the first FDA approved for hypothalamic obesity. Already approved for rare genetic forms of obesity involving the MC4R pathway, setmelanotide demonstrated 18.4% BMI reduction in the TRANSCEND trial of those with acquired hypothalamic obesity. This will be a useful tool for a rare condition where conventional therapies have limited effect. ir.rhythmtx.com/news-releases/…

The difference between GLP-1ra medications and bariatric surgery: when stopped the GLP-1ra benefits go away, the bariatric surgery benefits are long lasting and fade slowly over years and decades.

💉 High dose Wegovy 7.2mg weekly is now FDA approved 📊 The STEP UP trial demonstrated mean weight loss of 20.7%, compared to the 2.4mg dose yielding 17.5% ⚠️ There was a 16% higher rate of gastrointestinal events in the 7.2mg dose compared to the 2.4mg dose ✅ In patients who are tolerating Wegovy 2.4mg and would benefit from additional weight reduction, we will now have a higher dose to trial STEP UP trial results: thelancet.com/journals/landi…

The FDA has approved Wegovy HD (semaglutide 7.2 mg) for adults with obesity. In the STEP UP trial, average weight loss was about 21 percent at 72 weeks for those who stayed on treatment and 19 percent when including all participants. About one in three reached 25 percent or greater weight loss. prnewswire.com/news-releases/…

Honored to share that the new AACE Consensus Statement “Algorithm for Management of Adults With Type 2 Diabetes – 2026 Update” has been released for member review. Grateful to my coauthors and AACE colleagues for their incredible work on this important guidance for improving care for people with type 2 diabetes. endocrinepractice.org/article/S1530-…

People with GCK-MODY have lower liver fat than matched healthy control individuals without diabetes, suggesting a moderate decrease in glucokinase activity may be associated with reduced hepatic lipid accumulation. Read ➡️ doi.org/10.2337/dc25-1… @AmDiabetesAssn @ADA_DiabetesPro

Although GRADE can be dense and methodologically dry, it remains the most rigorous and transparent framework for rating evidence certainty and translating data into trustworthy, patient-centered recommendations in obesity pharmacotherapy. Congratulations to all involved on an exceptionally well-executed new Joint TOS–OMA–OAC GRADE-based guidance statement. onlinelibrary.wiley.com/doi/full/10.10…

This International Women's Day, I reflect on what it takes for a woman to thrive. More than skill, it takes resilience, mentorship, and the belief that your perspective belongs in the room. So grateful for the extraordinary women in my life! Happy International Women's Day 💙

🚨 New video: @MWeintraubMD (@nyulangone) and Dr. Michael Nauck dig into oral therapies, missed‑dose decisions, and what lean‑mass changes really mean during weight loss. They close with guidance on planning for long‑term care. docwirenews.com/post/oral-agen… @NeilFlochMD @BevTchangMD

New analysis shows how the @TheLancetEndo clinical obesity guidelines could shift diagnosis and change who receives treatment. Full interview out now. docwirenews.com/post/beyond-bm… @UCLAHealth @WorldObesity @MarynaChumakova @ECUHealthNC